Villanova Dott. Luca
Pubblicazioni su PubMed
-
Ventilation strategies in cardiogenic shock: Insights from the AltShock-2 registry.
Eur J Heart Fail2024 Aug;():. doi: 10.1002/ejhf.3409.
Sacco Alice, Montisci Andrea, Tavecchia Giovanni, Frea Simone, Bernasconi Davide, Colombo Costanza N J, Bertolin Stephanie, Viola Giovanna, Villanova Luca, Briani Martina, Patrini Lisa, Bocchino Pier Paolo, Sorini Dini Carlotta, D'Ettore Nicoletta, Bertaina Maurizio, Iannaccone Mario, Potena Luciano, Bertoldi Letizia, Valente Serafina, Camporotondo Rita, Marini Marco, Pagnesi Matteo, Metra Marco, De Ferrari Gaetano, Oliva Fabrizio, Morici Nuccia, Pappalardo Federico, Tavazzi Guido,
Abstract
AIMS:
To describe the use and the relation to outcome of different ventilation strategies in a contemporary, large, prospective registry of cardiogenic shock patients.
METHODS AND RESULTS:
Among 657 patients enrolled from March 2020 to November 2023, 198 (30.1%) received oxygen therapy (OT), 96 (14.6%) underwent non-invasive ventilation (NIV), and 363 (55.3%) underwent invasive mechanical ventilation (iMV). Patients in the iMV group were significantly younger compared to those in the NIV and OT groups (63 vs. 69?years, p?0.001). There were no significant differences between groups regarding cardiovascular risk factors. Patients with SCAI B and C were more frequently treated with OT and NIV compared to iMV (65.1% and 65.4% vs. 42.6%, respectively, p?>?0.001), while the opposite trend was observed in SCAI D patients (12% and 12.2% vs. 30.9%, respectively, p?0.001). All-cause mortality at 24?h did not differ amongst the three groups. The 60-day mortality rates were 40.2% for the iMV group, 26% for the OT group, and 29.3% for the NIV group (p?=?0.005), even after excluding patients with cardiac arrest at presentation. In the multivariate analysis including SCAI stages, NIV was not associated with worse mortality compared to iMV (hazard ratio 1.97, 95% confidence interval 0.85-4.56), even in more severe SCAI stages such as D.
CONCLUSIONS:
Compared to previous studies, we observed a rising trend in the utilization of NIV among cardiogenic shock patients, irrespective of aetiology and SCAI stages. In this clinical scenario, NIV emerges as a safe option for appropriately selected patients.
© 2024 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Guarda su PubMed
-
Transitioning to Palliative Care in an Italian Cardiac Intensive Care Unit Network.
Am J Crit Care2024 Mar;33(2):145-148. doi: 10.4037/ajcc2024535.
Sacco Alice, Pagnesi Matteo, Frea Simone, Briani Martina, Dini Carlotta Sorini, Bertaina Maurizio, Marini Marco, Trombara Filippo, Villanova Luca, Ravera Amelia, Tavazzi Guido, Pappalardo Federico, Morici Nuccia, Potena Luciano
Abstract
BACKGROUND:
Recent data indicate that end-of-life management for patients affected by acute decompensated heart failure in cardiac intensive care units is aggressive, with late or no engagement of palliative care teams.
OBJECTIVE:
To assess current palliative care and end-of-life practices in a contemporary Italian multicenter registry of patients with cardiogenic shock due to acute decompensated heart failure.
METHODS:
A survey-based approach was used to collect data on palliative care and end-of-life management practices. The AltShock-2 registry enrolled patients with cardiogenic shock from 12 participating centers. A subset of 153 patients with cardiogenic shock due to acute decompensated heart failure enrolled between March 2020 and March 2023 was analyzed, with a focus on early engagement of palliative care teams and deactivation of implantable cardioverter-defibrillators (ICDs).
RESULTS:
"Do not resuscitate" orders were documented in patient records in only 5 of 12 centers (42%). Palliative care teams were engaged for 21 of 153 enrolled patients (13.7%). Among the 51 patients with ICDs, 6 of 17 patients who died (35%) had defibrillator deactivation. Of the 17 patients who died, 13 died in the hospital and 4 died within 6 months after discharge; 1 patient had ICD deactivation supported by palliative care services at home.
CONCLUSIONS:
Therapy-limiting practices, including ICD deactivation, are not routine in the Italian centers participating in this study. The results emphasize the importance of integrating palliative care as a simultaneous process with intensive care to address the unmet needs of these patients and their families.
©2024 American Association of Critical-Care Nurses.
Guarda su PubMed
-
Sex-related differences in patients presenting with heart failure-related cardiogenic shock.
Clin Res Cardiol2024 Apr;113(4):612-625. doi: 10.1007/s00392-024-02392-8.
Sundermeyer Jonas, Kellner Caroline, Beer Benedikt N, Besch Lisa, Dettling Angela, Bertoldi Letizia Fausta, Blankenberg Stefan, Dauw Jeroen, Dindane Zouhir, Eckner Dennis, Eitel Ingo, Graf Tobias, Horn Patrick, Jozwiak-Nozdrzykowska Joanna, Kirchhof Paulus, Kluge Stefan, Linke Axel, Landmesser Ulf, Luedike Peter, Lüsebrink Enzo, Majunke Nicolas, Mangner Norman, Maniuc Octavian, Möbius-Winkler Sven, Nordbeck Peter, Orban Martin, Pappalardo Federico, Pauschinger Matthias, Pazdernik Michal, Proudfoot Alastair, Kelham Matthew, Rassaf Tienush, Scherer Clemens, Schulze Paul Christian, Schwinger Robert H G, Skurk Carsten, Sramko Marek, Tavazzi Guido, Thiele Holger, Villanova Luca, Morici Nuccia, Winzer Ephraim B, Westermann Dirk, Schrage Benedikt
Abstract
BACKGROUND:
Heart failure-related cardiogenic shock (HF-CS) accounts for a significant proportion of all CS cases. Nevertheless, there is a lack of evidence on sex-related differences in HF-CS, especially regarding use of treatment and mortality risk in women vs. men. This study aimed to investigate potential differences in clinical presentation, use of treatments, and mortality between women and men with HF-CS.
METHODS:
In this international observational study, patients with HF-CS (without acute myocardial infarction) from 16 tertiary-care centers in five countries were enrolled between 2010 and 2021. Logistic and Cox regression models were used to assess differences in clinical presentation, use of treatments, and 30-day mortality in women vs. men with HF-CS.
RESULTS:
N?=?1030 patients with HF-CS were analyzed, of whom 290 (28.2%) were women. Compared to men, women were more likely to be older, less likely to have a known history of heart failure or cardiovascular risk factors, and lower rates of highly depressed left ventricular ejection fraction and renal dysfunction. Nevertheless, CS severity as well as use of treatments were comparable, and female sex was not independently associated with 30-day mortality (53.0% vs. 50.8%; adjusted HR 0.94, 95% CI 0.75-1.19).
CONCLUSIONS:
In this large HF-CS registry, sex disparities in risk factors and clinical presentation were observed. Despite these differences, the use of treatments was comparable, and both sexes exhibited similarly high mortality rates. Further research is necessary to evaluate if sex-tailored treatment, accounting for the differences in cardiovascular risk factors and clinical presentation, might improve outcomes in HF-CS.
© 2024. The Author(s).
Guarda su PubMed
-
Ultrasound-Assisted, Catheter-Directed Thrombolysis for Acute Intermediate/High-Risk Pulmonary Embolism: Design of the Multicenter USAT IH-PE Registry and Preliminary Results.
J Clin Med2024 Jan;13(2):. doi: 619.
Colombo Claudia, Capsoni Nicolò, Russo Filippo, Iannaccone Mario, Adamo Marianna, Viola Giovanna, Bossi Ilaria Emanuela, Villanova Luca, Tognola Chiara, Curci Camilla, Morelli Francesco, Guerrieri Rossella, Occhi Lucia, Chizzola Giuliano, Rampoldi Antonio, Musca Francesco, De Nittis Giuseppe, Galli Mario, Boccuzzi Giacomo, Savio Daniele, Bernasconi Davide, D'Angelo Luciana, Garascia Andrea, Chieffo Alaide, Montorfano Matteo, Oliva Fabrizio, Sacco Alice
Abstract
Catheter-based revascularization procedures were developed as an alternative to systemic thrombolysis for patients with intermediate-high- and high-risk pulmonary embolisms. USAT IH-PE is a retrospective and prospective multicenter registry of such patients treated with ultrasound-facilitated, catheter-directed thrombolysis, whose preliminary results are presented in this study. The primary endpoint was the incidence of pulmonary hypertension (PH) at follow-up. Secondary endpoints were short- and mid-term changes in the echocardiographic parameters of right ventricle (RV) function, in-hospital and all-cause mortality, and procedure-related bleeding events. Between March 2018 and July 2023, 102 patients were included. The majority were at intermediate-high-risk PE (86%), were mostly female (57%), and had a mean age of 63.7 ± 14.5 years, and 28.4% had active cancer. Echocardiographic follow-up was available for 70 patients, and in only one, the diagnosis of PH was confirmed by right heart catheterization, resulting in an incidence of 1.43% (CI 95%, 0.036-7.7). RV echocardiographic parameters improved both at 24 h and at follow-up. In-hospital mortality was 3.9% (CI 95%, 1.08-9.74), while all-cause mortality was 11% (CI 95%, 5.4-19.2). Only 12% had bleeding complications, of whom 4.9% were BARC ? 3. Preliminary results from the USAT IH-PE registry showed a low incidence of PH, improvement in RV function, and a safe profile.
Guarda su PubMed
-
Cardiogenic Shock Integrated PHenotyping for Event Reduction: A Pilot Metabolomics Analysis.
Int J Mol Sci2023 Dec;24(24):. doi: 17607.
Morici Nuccia, Frigerio Gianfranco, Campolo Jonica, Fustinoni Silvia, Sacco Alice, Garatti Laura, Villanova Luca, Tavazzi Guido, Kapur Navin K, Pappalardo Federico
Abstract
Cardiogenic shock (CS) portends a dismal prognosis if hypoperfusion triggers uncontrolled inflammatory and metabolic derangements. We sought to investigate metabolomic profiles and temporal changes in IL6, Ang-2, and markers of glycocalyx perturbation from admission to discharge in eighteen patients with heart failure complicated by CS (HF-CS). Biological samples were collected from 18 consecutive HF-CS patients at admission (T0), 48 h after admission (T1), and at discharge (T2). ELISA analytical techniques and targeted metabolomics were performed Seven patients (44%) died at in-hospital follow-up. Among the survivors, IL-6 and kynurenine were significantly reduced at discharge compared to baseline. Conversely, the amino acids arginine, threonine, glycine, lysine, and asparagine; the biogenic amine putrescine; multiple sphingolipids; and glycerophospholipids were significantly increased. Patients with HF-CS have a metabolomic fingerprint that might allow for tailored treatment strategies for the patients' recovery or stabilization.
Guarda su PubMed
-
Association between left ventricular ejection fraction, mortality and use of mechanical circulatory support in patients with non-ischaemic cardiogenic shock.
Clin Res Cardiol2024 Apr;113(4):570-580. doi: 10.1007/s00392-023-02332-y.
Sundermeyer Jonas, Kellner Caroline, Beer Benedikt N, Besch Lisa, Dettling Angela, Bertoldi Letizia Fausta, Blankenberg Stefan, Dauw Jeroen, Dindane Zouhir, Eckner Dennis, Eitel Ingo, Graf Tobias, Horn Patrick, Jozwiak-Nozdrzykowska Joanna, Kirchhof Paulus, Kluge Stefan, Linke Axel, Landmesser Ulf, Luedike Peter, Lüsebrink Enzo, Majunke Nicolas, Mangner Norman, Maniuc Octavian, Winkler Sven Möbius, Nordbeck Peter, Orban Martin, Pappalardo Federico, Pauschinger Matthias, Pazdernik Michal, Proudfoot Alastair, Kelham Matthew, Rassaf Tienush, Scherer Clemens, Schulze Paul Christian, Schwinger Robert H G, Skurk Carsten, Sramko Marek, Tavazzi Guido, Thiele Holger, Villanova Luca, Morici Nuccia, Westenfeld Ralf, Winzer Ephraim B, Westermann Dirk, Schrage Benedikt
Abstract
BACKGROUND:
Currently, use of mechanical circulatory support (MCS) in non-ischaemic cardiogenic shock (CS) is predominantly guided by shock-specific markers, and not by markers of cardiac function. We hypothesise that left ventricular ejection fraction (LVEF) can identify patients with a higher likelihood to benefit from MCS and thus help to optimise their expected benefit.
METHODS:
Patients with non-ischaemic CS and available data on LVEF from 16 tertiary-care centres in five countries were analysed. Cox regression models were fitted to evaluate the association between LVEF and mortality, as well as the interaction between LVEF, MCS use and mortality.
RESULTS:
N?=?807 patients were analysed: mean age 63 [interquartile range (IQR) 51.5-72.0] years, 601 (74.5%) male, lactate 4.9 (IQR 2.6-8.5) mmol/l, LVEF 20 (IQR 15-30) %. Lower LVEF was more frequent amongst patients with more severe CS, and MCS was more likely used in patients with lower LVEF. There was no association between LVEF and 30-day mortality risk in the overall study cohort. However, there was a significant interaction between MCS use and LVEF, indicating a lower 30-day mortality risk with MCS use in patients with LVEF???20% (hazard ratio 0.72, 95% confidence interval 0.51-1.02 for LVEF???20% vs. hazard ratio 1.31, 95% confidence interval 0.85-2.01 for LVEF?>?20%, interaction-p?=?0.017).
CONCLUSION:
This retrospective study may indicate a lower mortality risk with MCS use only in patients with severely reduced LVEF. This may propose the inclusion of LVEF as an adjunctive parameter for MCS decision-making in non-ischaemic CS, aiming to optimise the benefit-risk ratio.
© 2023. The Author(s).
Guarda su PubMed
-
Clinical presentation, shock severity and mortality in patients with de novo versus acute-on-chronic heart failure-related cardiogenic shock.
Eur J Heart Fail2024 Feb;26(2):432-444. doi: 10.1002/ejhf.3082.
Sundermeyer Jonas, Kellner Caroline, Beer Benedikt N, Besch Lisa, Dettling Angela, Bertoldi Letizia Fausta, Blankenberg Stefan, Dauw Jeroen, Dindane Zouhir, Eckner Dennis, Eitel Ingo, Graf Tobias, Horn Patrick, Jozwiak-Nozdrzykowska Joanna, Kirchhof Paulus, Kluge Stefan, Linke Axel, Landmesser Ulf, Luedike Peter, Lüsebrink Enzo, Majunke Nicolas, Mangner Norman, Maniuc Octavian, Möbius Winkler Sven, Nordbeck Peter, Orban Martin, Pappalardo Federico, Pauschinger Matthias, Pazdernik Michal, Proudfoot Alastair, Kelham Matthew, Rassaf Tienush, Reichenspurner Hermann, Scherer Clemens, Schulze Paul Christian, Schwinger Robert H G, Skurk Carsten, Sramko Marek, Tavazzi Guido, Thiele Holger, Villanova Luca, Morici Nuccia, Winzer Ephraim B, Westermann Dirk, Gustafsson Finn, Schrage Benedikt
Abstract
AIMS:
Heart failure-related cardiogenic shock (HF-CS) accounts for a significant proportion of CS cases. Whether patients with de novo HF and those with acute-on-chronic HF in CS differ in clinical characteristics and outcome remains unclear. The aim of this study was to evaluate differences in clinical presentation and mortality between patients with de novo and acute-on-chronic HF-CS.
METHODS AND RESULTS:
In this international observational study, patients with HF-CS from 16 tertiary care centres in five countries were enrolled between 2010 and 2021. To investigate differences in clinical presentation and 30-day mortality, adjusted logistic/Cox regression models were fitted. Patients (n?=?1030) with HF-CS were analysed, of whom 486 (47.2%) presented with de novo HF-CS and 544 (52.8%) with acute-on-chronic HF-CS. Traditional markers of CS severity (e.g. blood pressure, heart rate and lactate) as well as use of treatments were comparable between groups. However, patients with acute-on-chronic HF-CS were more likely to have a higher CS severity and also a higher mortality risk, after adjusting for relevant confounders (de novo HF 45.5%, acute-on-chronic HF 55.9%, adjusted hazard ratio 1.38, 95% confidence interval 1.10-1.72, p?=?0.005).
CONCLUSION:
In this large HF-CS cohort, acute-on-chronic HF-CS was associated with more severe CS and higher mortality risk compared to de novo HF-CS, although traditional markers of CS severity and use of treatments were comparable. These findings highlight the vast heterogeneity of patients with HF-CS, emphasize that HF chronicity is a relevant disease modifier in CS, and indicate that future clinical trials should account for this.
© 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Guarda su PubMed
-
Differences between cardiogenic shock related to acute decompensated heart failure and acute myocardial infarction.
ESC Heart Fail2023 Dec;10(6):3472-3482. doi: 10.1002/ehf2.14510.
Bertaina Maurizio, Morici Nuccia, Frea Simone, Garatti Laura, Briani Martina, Sorini Carlotta, Villanova Luca, Corrada Elena, Sacco Alice, Moltrasio Marco, Ravera Amelia, Tedeschi Michele, Bertoldi Letizia, Lettino Maddalena, Saia Francesco, Corsini Anna, Camporotondo Rita, Colombo Costanza Natalia Julia, Bertolin Stephanie, Rota Matteo, Oliva Fabrizio, Iannaccone Mario, Valente Serafina, Pagnesi Matteo, Metra Marco, Sionis Alessandro, Marini Marco, De Ferrari Gaetano Maria, Kapur Navin K, Pappalardo Federico, Tavazzi Guido
Abstract
AIMS:
The present analysis from the multicentre prospective Altshock-2 registry aims to better define clinical features, in-hospital course, and management of cardiogenic shock complicating acutely decompensated heart failure (ADHF-CS) as compared with that complicating acute myocardial infarction (AMI-CS).
METHODS AND RESULTS:
All patients with AMI-CS or ADHF-CS enrolled in the Altshock-2 registry between March 2020 and February 2022 were selected. The primary objective was the characterization of ADHF-CS patients as compared with AMI-CS. In-hospital length of stay and mortality were secondary endpoints. One-hundred-ninety of the 238 CS patients enrolled in the aforementioned period were considered for the present analysis: 101 AMI-CS (80% ST-elevated myocardial infarction and 20% non-ST-elevated myocardial infarction) and 89 ADHF-CS. As compared with AMI-CS, ADHF-CS patients were younger [63 (IQR 59-76) vs. 67 (IQR 54-73) years, P = 0.01], but presented with higher creatinine [1.6 (IQR 1.0-2.6) vs. 1.2 (IQR 1.0-1.4) mg/dL, P
CONCLUSIONS:
ADHF-CS is characterized by a higher prevalence of end-organ and biventricular dysfunction at presentation, a longer hospital length of stay, and higher need of heart replacement therapies when compared with AMI-CS. In-hospital mortality was similar between the two aetiologies. Our data warrant development of new management protocols focused on CS aetiology.
© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Guarda su PubMed
-
Effect of a quality-improvement intervention on end-of-life care in cardiac intensive care unit.
Eur J Clin Invest2023 Jul;53(7):e13982. doi: 10.1111/eci.13982.
Sacco Alice, Tavecchia Giovanni, Ditali Valentina, Garatti Laura, Villanova Luca, Colombo Claudia, Viola Giovanna, Scavelli Francesca, Varrenti Marisa, Milani Martina, Morici Nuccia, Tavazzi Guido, Lissoni Barbara, Forni Lorena, Gorni Giovanna, Saporetti Giorgia, Oliva Fabrizio
Guarda su PubMed
-
Use of mechanical circulatory support in patients with non-ischaemic cardiogenic shock.
Eur J Heart Fail2023 Apr;25(4):562-572. doi: 10.1002/ejhf.2796.
Schrage Benedikt, Sundermeyer Jonas, Beer Benedikt Norbert, Bertoldi Letizia, Bernhardt Alexander, Blankenberg Stefan, Dauw Jeroen, Dindane Zouhir, Eckner Dennis, Eitel Ingo, Graf Tobias, Horn Patrick, Kirchhof Paulus, Kluge Stefan, Linke Axel, Landmesser Ulf, Luedike Peter, Lüsebrink Enzo, Mangner Norman, Maniuc Octavian, Winkler Sven Möbius, Nordbeck Peter, Orban Martin, Pappalardo Federico, Pauschinger Matthias, Pazdernik Michal, Proudfoot Alastair, Kelham Matthew, Rassaf Tienush, Reichenspurner Hermann, Scherer Clemens, Schulze Paul Christian, Schwinger Robert H G, Skurk Carsten, Sramko Marek, Tavazzi Guido, Thiele Holger, Villanova Luca, Morici Nuccia, Wechsler Antonia, Westenfeld Ralf, Winzer Ephraim, Westermann Dirk
Abstract
AIMS:
Despite its high incidence and mortality risk, there is no evidence-based treatment for non-ischaemic cardiogenic shock (CS). The aim of this study was to evaluate the use of mechanical circulatory support (MCS) for non-ischaemic CS treatment.
METHODS AND RESULTS:
In this multicentre, international, retrospective study, data from 890 patients with non-ischaemic CS, defined as CS due to severe de-novo or acute-on-chronic heart failure with no need for urgent revascularization, treated with or without active MCS, were collected. The association between active MCS use and the primary endpoint of 30-day mortality was assessed in a 1:1 propensity-matched cohort. MCS was used in 386 (43%) patients. Patients treated with MCS presented with more severe CS (37% vs. 23% deteriorating CS, 30% vs. 25% in extremis CS) and had a lower left ventricular ejection fraction at baseline (21% vs. 25%). After matching, 267 patients treated with MCS were compared with 267 patients treated without MCS. In the matched cohort, MCS use was associated with a lower 30-day mortality (hazard ratio 0.76, 95% confidence interval 0.59-0.97). This finding was consistent through all tested subgroups except when CS severity was considered, indicating risk reduction especially in patients with deteriorating CS. However, complications occurred more frequently in patients with MCS; e.g. severe bleeding (16.5% vs. 6.4%) and access-site related ischaemia (6.7% vs. 0%).
CONCLUSION:
In patients with non-ischaemic CS, MCS use was associated with lower 30-day mortality as compared to medical therapy only, but also with more complications. Randomized trials are needed to validate these findings.
© 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Guarda su PubMed
-
Left Ventricular Unloading in Acute on Chronic Heart Failure: From Statements to Clinical Practice.
J Pers Med2022 Sep;12(9):. doi: 1463.
Sacco Alice, Morici Nuccia, Oreglia Jacopo Andrea, Tavazzi Guido, Villanova Luca, Colombo Claudia, Garatti Laura, Mondino Michele Giovanni, Nava Stefano, Pappalardo Federico
Abstract
Cardiogenic shock remains a deadly complication of acute on chronic decompensated heart failure (ADHF-CS). Despite its increasing prevalence, it is incompletely understood and therefore often misdiagnosed in the early phase. Precise diagnosis of the underlying cause of CS is fundamental for undertaking the correct therapeutic strategy. Temporary mechanical circulatory support (tMCS) is the mainstay of management: identifying and selecting optimal patients through understanding of the hemodynamics and a prompt profiling and timing, is key for success. A recent statement from the American Heart Association provided pragmatic suggestions on tMCS device selection, escalation, and weaning strategies. However, several areas of uncertainty still remain in clinical practice. Accordingly, we present an overview of the main pitfalls that can occur during patients' management with tMCS through a clinical case. This case illustrates the strict interdependency between left ventricular unloading and right ventricular dysfunction in the case of low filling pressures. Moreover, it further illustrates the pivotal role of stepwise escalation of therapy in a patient with an ADHF-CS and its peculiarities as compared to other forms of acute heart failure.
Guarda su PubMed
-
Percutaneous Coronary Revascularization after Out-of-Hospital Cardiac Arrest: A Review of the Literature and a Case Series.
J Clin Med2022 Mar;11(5):. doi: 1395.
Scavelli Francesca, Cartella Iside, Montalto Claudio, Oreglia Jacopo Andrea, Villanova Luca, Garatti Laura, Colombo Claudia, Sacco Alice, Morici Nuccia
Abstract
Out-of-hospital cardiac arrest (OHCA) is still associated with high mortality and severe complications, despite major treatment advances in this field. Ischemic heart disease is a common cause of OHCA, and current guidelines clearly recommend performing immediate coronary angiography (CAG) in patients whose post-resuscitation electrocardiogram shows ST-segment elevation (STE). Contrarily, the optimal approach and the advantage of early revascularization in cases of no STE is less clear, and decisions are often based on the individual experience of the center. Numerous studies have been conducted on this topic and have provided contradictory evidence; however, more recently, results from several randomized clinical trials have suggested that performing early CAG has no impact on overall survival in patients without STE.
Guarda su PubMed
-
Effect of landiolol in patients with tachyarrhythmias and acute decompensated heart failure (ADHF): a case series.
ESC Heart Fail2022 Feb;9(1):766-770. doi: 10.1002/ehf2.13763.
Ditali Valentina, Garatti Laura, Morici Nuccia, Villanova Luca, Colombo Claudia, Oliva Fabrizio, Sacco Alice
Abstract
Tachycardia and rapid tachyarrhythmias are common in acute clinical settings and may hasten the deterioration of haemodynamics in patients with acute decompensated heart failure (ADHF), treated with inotropes. The concomitant use of a short-acting ?1-selective beta-blocker, such as landiolol, could rapidly and safely restore an adequate heart rate without any negative inotropic effect. We present a case series of five patients with left ventricular dysfunction, admitted to our Intensive Cardiac Care Unit with ADHF deteriorated to cardiogenic shock, treated with a combination of landiolol and inotropes. Landiolol was effective in terms of rate control and haemodynamics optimization, enabling de-escalation of catecholamine dosing in all patients. The infusion was always well tolerated without hypotension. In conclusion, a continuous infusion of a low dose of landiolol (3-16 mcg/kg/min) to manage tachycardia and ventricular or supraventricular tachyarrhythmias in haemodynamically unstable patients may be considered.
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Guarda su PubMed
-
Predicting survival in patients with acute decompensated heart failure complicated by cardiogenic shock.
Int J Cardiol Heart Vasc2021 Jun;34():100809. doi: 100809.
Morici Nuccia, Viola Giovanna, Antolini Laura, Alicandro Gianfranco, Dal Martello Michela, Sacco Alice, Bottiroli Maurizio, Pappalardo Federico, Villanova Luca, De Ponti Laura, La Vecchia Carlo, Frigerio Maria, Oliva Fabrizio, Fried Justin, Colombo Paolo, Garan Arthur Reshad
Abstract
BACKGROUND:
Acute decompensated heart failure (ADHF) complicated by cardiogenic shock (CS) has unique pathophysiological background requiring specific patient stratification, management and therapeutic targets. Accordingly, the aim of this study was to derive a simple stratification tool to predict survival in patients with ADHF complicated by CS.
METHODS AND RESULTS:
Using logistic regression, univariable testing was performed to identify the variables potentially associated with 28-day mortality. We propose a new logistic model (ALC-Shock score) based on three easy parameters (age, serum creatinine and serum lactate at the ICU admission) as a powerful predictor of survival or successful bridge to heart replacement therapy at 28-day follow-up in this specific population. A multivariable analysis (logistic model) was performed to evaluate the association between selected variables and outcome (overall death at 28-day follow up). The score was then validated in a different cohort of 93 ADHF-CS patients and compared to a previous developed score (the Cardshock score).Overall, 28-day mortality was 34%. The ALC-shock score showed better discrimination (Area Under the Curve-AUC- 0.82; 95% CI 0.73-0.91) as compared to the Cardshock score (AUC 0.67; 95% CI 0.55-0.79) (p = 0.009) to predict 28-days overall mortality. In the validation cohort the AUC for the ALC-shock score was 0.66.
CONCLUSIONS:
A simple score including age, lactates and creatinine on admission could be considered to predict short-term mortality in CS-ADHF patients in order to drive towards a treatment intensification.
© 2021 The Author(s).
Guarda su PubMed
-
Appropriateness of use criteria in echocardiography: an Italian experience.
J Cardiovasc Med (Hagerstown)2017 Aug;18(8):635-636. doi: 10.2459/JCM.0000000000000510.
Morrone Doralisa, Villanova Luca, Huqi Alda, Guarini Giacinta, Marzilli Mario
Guarda su PubMed
